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Abstract
Background Colorectal carcinomas with high-frequency mi-
crosatellite instability (MSI-H) account for 15% of all colo-
rectal cancers, including 12% of sporadic cases and 3% of
cancers associated with Lynch syndrome (also known as he-
reditary nonpolyposis colorectal cancer syndrome, HNPCC).
Lynch syndrome is an autosomal dominant hereditary cancer
syndrome, caused by germline mutations in mismatch repair
genes, including MLH1, MSH2, MSH6 and PMS2.
Methods Published articles from peer-reviewed journals were
obtained from PubMed, Google Scholar and Clinicaltrials.gov.
Based on the recent research data, we provide an update on the
MSI testing, along with the evolving role of MSI in diagnosis,
prognosis and treatment of colorectal cancers.
Results Studies have led to significant advances in the molec-
ular pathogenesis and clinicopathological characteristics of
MSI-H colorectal cancers. Emerging evidence suggests that
colorectal cancers with MSI-H show different outcome and
treatment response from those with microsatellite stable
(MSS) tumors. Therefore, MSI testing is essential not only
in the genetic context, but it may also have important prog-
nostic and predictive value of response to chemotherapy and
immunotherapy.
Conclusions Many experts and professional authorities have
recommended a universal MSI testing in all individuals newly
diagnosed with colorectal cancers.
Keywords Microsatellite instability .Mismatchrepair .Lynch
syndrome . Colorectal cancer . Cancer treatment .
Chemotherapy . Immunotherapy
Introduction
Colorectal cancer is a major health problem in Western coun-
tries, representing the second most commonly diagnosed ma-
lignancy in males and third in females and accounting for
about 700,000 deaths per year [1, 2]. The majority of colorec-
tal cancers display chromosomal instability and follow the
classical adenoma-carcinoma progressive pathway.
However, a subset of 15% of colorectal cancers displays
DNA mismatch repair (MMR) deficiency and shows high-
level microsatellite instability (MSI-H) [2, 3]. Colorectal can-
cers with MSI-H can occur as sporadic fashion or in the con-
text of Lynch syndrome, also known as hereditary non-
polyposis colorectal cancer syndrome (HNPCC) [4, 5].
Thus, colorectal cancers can be classified under twomolecular
phenotypes, i.e., microsatellite stable (MSS) and microsatel-
lite unstable or MSI-H phenotype [6].
MSI-H colorectal cancer has distinct clinicopathological
features, including younger age of onset, proximal location,
florid lymphocytic reaction, mucinous/signet ring differentia-
tion and medullary growth pattern [6–8]. MSI is a critical
DNA marker for the diagnosis of Lynch syndrome. Recent
data also suggest that MSI status in colorectal cancers could
provide valuable information for prognostic estimation and
treatment stratification [9–11]. We provide here a brief review
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on recent development of MSI in diagnosis, prognosis and
treatment of colorectal carcinoma.
Microsatellite Instability Testing
Lynch syndrome is caused by inherited defects in mismatch
repair (MMR) genes MLH1, MSH2, MSH6 and PMS2 [4–6].
The presence of MSI-H and/or the absence of one or more of
the MMR proteins by immunohistochemistry (IHC) in the
tumor suggest MMR deficiency. MSI-H can be also caused
by somatic hypermethylation of theMLH1 promoter, which is
often associated with a BRAF c.1799T>A (p.V600E) muta-
tion [12–14]. These somatic mutations are typically associated
with sporadic colorectal carcinomas. MSI can be tested by
either polymerase chain reaction (PCR)-based DNA tech-
nique or immunohistochemical staining on tumor tissue.
Steps for the Microsatellite Instability DNATesting
MSI DNA testing is a PCR-based method that amplifies DNA
at several microsatellite sites from a person’s tumor tissue sam-
ple. Interpretation of the profiles requires a comparison with
normal DNA from each patient. The National Cancer Institute
Workshop agreed on five microsatellite markers necessary to
determine MSI that include two mononucleotide markers—
BAT25/26 and three dinucleotide markers—D2S123, D5S346
and D17S250 [15, 16]. Some laboratories use commercially
available testing kit, such as five-marker mononucleotide or
quasimonomorphic panel [17, 18]. All of these markers are
highly concordant with respect to the testing results [16].
Testing steps by PCR technique are listed in Table 1.
Based on the MSI status, colorectal cancers can be classi-
fied into three groups: (1) if 30% or more of the repeats are
unstable, a tumor is classified as MSI-high (MSI-H); (2) if
fewer than 30% of repeats are unstable, a tumor is classified
as MSI-low (MSI-L); and (3) if no repeats are unstable, a
tumor is classified as microsatellite stable (MSS) [16]. A
MSI-L profile does not appear to be a good predictor of
Lynch syndrome, so this result is grouped with the MSS type
and does not lead to further testing.
Steps for the Immunohistochemistry Testing
Immunohistochemistry is widely used to identify the loss of
one or more of the mismatch repair proteins (MLH1, MSH2,
MSH6 and PMS2) [6, 8, 16]. TheseMMR proteins are usually
expressed in normal tissue and show positive nuclear staining
on IHC. The absence of specific staining suggests an under-
lying inactivation of one or more MMR genes. Tumors
displaying loss of an MMR protein can be collectively re-
ferred to as MMR deficiency and are considered to be MSI-
H, whereas those with intact MMR proteins are expected to be
MSS or MSI-low [6, 8, 16].
The most common abnormal IHC staining pattern is simul-
taneous loss of MLH1 and PMS2, with normal staining of
MSH2 and MSH6 (Fig. 1). This could indicate either Lynch
syndrome or MMR deficiency in a sporadic tumor. Further
testing for BRAF V600E mutation and MLH1 promoter
hypermethylation can differentiate sporadic tumor from
Lynch syndrome-associated cancer [6, 16]. Testing steps by
immunohistochemical staining are listed in Table 2. The other
IHC profiles, such as combined MSH2/MSH6 loss or isolated
loss of MSH6 or PMS2, are more likely to be associated with
Lynch syndrome due to a germline mutation in one of these
genes [6, 16]. Germline mutation analysis can be done on
blood leukocyte DNA or normal tissue of the patient.
Concordance Rate Between MSI and IHC Testing
Both MSI DNA testing and IHC are sensitive and specific.
The reported sensitivity of MSI DNA testing is 89% for
MLH1/MSH2 and 77% for MSH6 [19]. The reported sensi-
tivity of IHC for the MMR proteins is 77 to 83% [20, 21]. The
concordance rate between IHC and MSI testing is over 92%
[20, 21]. In practice, PCR and IHC testing often act as com-
plementary tests; while both are sensitive and specific for mis-
match repair deficiency, neither is perfect, and both will miss
some mismatch repair-deficient tumors. To increase the detec-
tion rate, these two tests may be performed synergistically to
detect cases that maybe missed by either test alone [22]. Easy
performance and cost-effectiveness are two of the advantages
of IHC. Moreover, IHC testing is helpful in identifying the
specific defective protein and can guide germline testing to
that specific gene.
Diagnostic Role of MSI Testing
MSI Deficiency and Lynch Syndrome
MSI deficiency is the hallmark of genetic aberration of
Lynch syndrome [3–5]. This syndrome is an autosomal
dominant disorder, caused by a germline mutation in one
of the mismatch repair genes: MLH1, MSH2, MSH6 and
Table 1 Steps for the microsatellite instability DNA testing
(1) Do a microsatellite instability test.
(2) If the microsatellite instability test result is positive, use sequential
BRAF V600E and MLH1 promoter hypermethylation testing to
differentiate sporadic and Lynch syndrome-associated colorectal can-
cers. First do a BRAF V600E test.
(3) If the BRAF V600E test is negative, do an MLH1 promoter
hypermethylation test.
(4) If the MLH1 promoter hypermethylation test is negative, confirm
Lynch syndrome by genetic testing of germline DNA.
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PMS2 [3–5, 20–23]. The majority of Lynch patients can
be attributed to the mutation of MLH1 or MSH2, account-
ing for about 90% of the cases identified [23, 24]. The
mutation of MSH6 only accounts for a small portion of
Lynch syndrome. Isolated loss of PMS2 is rare in patients
with Lynch syndrome [23–25].
The flowchart in Fig. 2 shows MSI testing strategies for
Lynch syndrome in people with colorectal cancer.
Fig. 1 Immunohistochemistry
for mismatch repair proteins in
two colonic cancers. Patient 1
(panels a–e) shows a poorly
differentiated adenocarcinoma (a)
which is positive for MLH1 (b),
MSH2 (c), MSH6 (d) and PMS2
(e), indicating MSS phenotype.
Patient 2 (panels f–j) shows a
moderately differentiated
adenocarcinoma (f) with a MSI-H
phenotype. Note the loss of nu-
clear staining for MLH1 (g) and
PMS2 (j) but normal staining for
MSH2 (h) and MSH6 (i). This
tumor was subsequently tested for
BRAF V600E and MLH1 pro-
moter hypermethylation and did
not reveal any abnormality. The
findings in patient 2 are sugges-
tive of Lynch syndrome; there-
fore, DNA germline testing is
recommended
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Lynch syndrome accounts for about 3% (one in 30) of
colorectal cancers and is estimated to lead to over 1100 colo-
rectal cancers each year in the UK. The diagnosis of Lynch
syndrome is essential since the patient has a high risk for
developing many other cancers and needs appropriate surveil-
lance. It is also important to identify family members carrying
a defect MSI gene because they are at increased risk of devel-
oping cancers as well. The lifetime risk of colorectal cancer in
individuals with Lynch syndrome is between 30 and 70%, in
contrast to 5.5% in the general population [5, 26]. Patients
with Lynch syndrome also have a high risk of developing
extra-colorectal cancers, including endometrial carcinoma,
ovary, small bowel, stomach, bladder, brain, kidney, biliary
tract and gallbladder cancers, and skin sebaceous tumors
[27–29]. For endometrial cancer, the cumulative risk in
Lynch syndrome patients by 70 years is between 32 and
42% [27, 28].
Patients with Lynch syndrome have earlier age of colorec-
tal cancer diagnosis at 44–61 years compared with 69 years in
sporadic cases [26]. Approximately 70% of colon cancers in
Lynch syndrome arise in the proximal colon [3].
Histologically, Lynch syndrome-related colorectal cancers
tend to be mucinous and poorly differentiated with signet ring
cells [6–8]. Another striking sign of MSI-H colorectal cancer
is a high density of tumor-infiltrating lymphocytes [7].
Despite poor histological differentiation, the biological behav-
ior of MSI-H colorectal carcinoma is less aggressive com-
pared to that of MSS colorectal cancer [5–8].
MSI Deficiency in Sporadic Colorectal Cancers
MSI-H profile is observed in about 12% of sporadic colorectal
cancers. The immunohistochemical finding in MSI-H sporad-
ic tumors is usually simultaneous loss of MLH1 and PMS2.
This is caused byMLH1 promoter hypermethylation, which is
often associated with a BRAF c.1799T>A (p.V600E) muta-
tion. This somatic mutation turns off the production of MLH1
mRNA and, therefore, the MLH1 protein is absent in cancer
cells (Fig. 1) [30, 31]. The mutation of BRAF V600E gene is
distinct in sporadic MSI-H tumors and not observed in tumors
with germline mutations [32].
If loss of MLH1/PMS2 protein expression is observed,
analysis of BRAF V600E mutation or analysis of methylation
of the MLH1 promoter should be conducted to rule out a
Table 2 Steps for the immunohistochemistry testing
(1) Do an immunohistochemistry 4-panel test for MLH1, MSH2, MSH6
and PMS2.
(2) If theMLH1 immunohistochemistry result is abnormal, use sequential
BRAF
(3) V600E and MLH1 promoter hypermethylation testing to differentiate
sporadic and Lynch syndrome-associated colorectal cancers. First do a
BRAF V600E test.
(4) If the BRAF V600E test is negative, do an MLH1 promoter
hypermethylation test.
(5) If the MLH1 promoter hypermethylation test is negative, confirm
Lynch syndrome by genetic testing of germline DNA.
In term of steps 2–4, if the MSH2, MSH6 or PMS2 immunohistochem-
istry results are abnormal, confirm Lynch syndrome by subsequent ge-
netic testing of germline DNA
Fig. 2 NICE recommended universal screening strategy for Lynch syndrome Reproduced from reference [60]
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sporadic case. If tumor is MLH1/PMS2-deficient and somatic
BRAF mutation is not detected or MLH1 promoter methyla-
tion is not identified, this MSI-H is less likely to be sporadic,
and testing for germline mutations is indicated (Table 2).
Prognostic Value of MSI Status for Colorectal
Cancers
MSI-H colorectal cancers, including sporadic and Lynch
syndrome-related familial colorectal cancers, tend to have a less
aggressive clinical behavior and a favorable prognosis com-
pared to MSS tumors [33, 34]. This phenomenon has been
repeatedly observed in retrospective studies, large trial studies
and meta-analysis [35–38]. For instance, a recent meta-analysis
from 32 studies with 1277 MSI-H cases included 7642 patients
with stage I–IV colorectal cancers. The authors [38] found that
cancers with MSI-H have a significantly better prognosis com-
pared to those with MSS, i.e., intact mismatch repair. The esti-
mated hazard ratio (HR) for overall survival associated with
MSI-H was 0.65 (95% confidence interval (CI), 0.59 to 0.71).
This benefit was maintained restricting analyses to clinical trial
patients (HR = 0.69; 95% CI, 0.56 to 0.85) and patients with
locally advanced colorectal cancers (HR = 0.67; 95% CI, 0.58
to 0.78). In a study of 2940 patients with stage I–III colorectal
cancers who underwent complete resection, Kim et al. [39]
noted that patients with MSI-H had a better clinical prognosis
and these tumors were more often associated with local recur-
rence or peritoneal metastases, while the extra-abdominal recur-
rence was less frequent compared to MSI-L/MSS tumors.
Mohan et al. [40] carried out a single-center study including
1250 colorectal patients and found that MSI-H was associated
with a reduced risk of nodal and distant metastases, with an
improved disease free survival (DFS) in stage I/II colorectal
cancers. However, when MSI-H tumors progressed to stage
III, these patients had worse outcomes and the tumors exhibited
more aggressive pathological features including higher rates of
lymphovascular invasion and perineural invasion than stage I/II
MSI-H tumors. In a pooled analysis of 3063 patients from four
phase III studies in first-line treatment of metastatic colorectal
cancers, Venderbosch et al. [41] found patients with deficient
MMR (dMMR) had significantly reduced progression-free sur-
vival and overall survival for advanced colorectal cancers and
this poor prognosis of dMMR appears to be driven by BRAF
mutation. These results suggest that the better prognosis of
MSI-H tumors is more apparent for stage I/II early disease,
but this predictive trend gradually disappears or even turns into
a negative correlation as tumor progresses into advanced stages.
It has been suggested that the improved prognosis of MSI-
H cancers may be resulted from the pronounced anti-tumoral
immune response of the host [42–44]. Tumors withMSI-H are
hypermutated and express abundant peptides that serve as
neoantigens to elicit a brisk immune response characterized
by abundant tumor-infiltrating lymphocytes, including forma-
tion of lymphoid aggregates, medullary growth pattern and
Crohn-like lymphocytic reaction [5, 7, 42, 43]. This represents
an active immune response to the tumor, a known positive
prognostic factor for colorectal carcinoma [42–44]. Due to
unstable and hyper-mutational nature, colorectal cancers with
MSI-H profile also tend to express high level of checkpoint
proteins, including programmed death 1 (PD-1) and pro-
grammed death ligand 1 (PD-L1) [45], which makes MSI-H
tumors more responsive to immunotherapy with PD-L1/PD-1
blockade (see the following discussion).
Predictive Value ofMSI Status for Colorectal Cancer
Treatment
MSI Status and Chemotherapy Response
Fluorouracil (5-FU) combined with leucovorin is considered
as standard care for patients with stage II colorectal cancer.
Data indicate that 5-FU-based adjuvant chemotherapy is inef-
fective in stage II cancer patients with MSI-H [46], consistent
with the preclinical data showing that MMR deficiency is
associated with 5-FU resistance in colorectal cancer cells
[47, 48]. Given the fact of favorable prognosis and lack of
benefit from 5-FU-based adjuvant chemotherapy, many au-
thors suggest that stage II colorectal cancer patients with a
MSI-H phenotype should not be referred to adjuvant chemo-
therapy [49–53].
The chemotherapy regimen of folinic acid, 5-FU and
oxaliplatin (FOLFOX), which is the standard adjuvant treat-
ment regimen after surgical resection of stage III (lymph node-
positive) cancers or for metastatic disease, however, does ap-
pear to be effective in patients with MSI-H cancers, similar to
their MSS countertype [54–57]. Therefore, stage III colorectal
cancer patients can be offered for adjuvant FOLFOX treat-
ment, irrespective of MMR status. However, so far only lim-
ited data are available from prospective clinical trials and fur-
ther studies are required. Nevertheless, knowing the MSI sta-
tus of the patient may help oncologists to draw up a most
appropriate, personalized treatment plan.
MSI Status and Immunotherapy Response
Recent studies have shown that metastatic colorectal cancers
with MSI-H respond favorably to immune checkpoint inhibi-
tors [11, 58, 59]. These tumors tend to have high expression of
checkpoint proteins, including PD-1 and PD-L1, which inter-
fere with the body’s antitumor T cell response. By disabling
these proteins, checkpoint inhibitors enable T cells to attack
and kill tumor cells, allowing the immune system to do its job
more effectively [11, 58–60].
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Le et al. [11] conducted a phase II trial in patients with
metastatic colorectal cancers with or without MMR deficiency
to evaluate the clinical activity of an antibody to PD-1 recep-
tor, called pembrolizumab (Keytruda). Patients with MSI-H
colorectal cancers and other carcinomas with MSI-H profile,
including endometrial, gastric, small bowel carcinomas and
ampullary or cholangiocarcinoma, had high rates of
immune-related objective response (40 and 71%, respective-
ly) and high rates of immune-related progression-free survival
at 20 weeks (78 and 67%). No responses were seen in MSS
colorectal cancer patients, and the 20-week progression-free
survival was only 11%.
More recently, the promising antitumor activity of
nivolumab (Opdivo), another anti-PD-1 monoclonal antibody,
in patients with MSI-H metastatic colorectal cancers was also
sustained in an update of the phase II CheckMate-142 trial
presented at the 2017 Gastrointestinal Cancers Symposium
[61]. At a median follow-up of 7.4 months (range, 0.3–
25.3), the overall response rate with single-agent nivolumab
in a cohort of 74 MSI-H patients was 31.1%. The median
progression-free survival (PFS) was 9.6 months (95% CI,
4.3–NE), and the 12-month PFS rate was 48.4% (95% CI,
33.6–61.7). The median overall survival (OS) had not been
reached (95% CI, 17.1–NE), and the 12-month OS rate was
73.8% (95% CI, 59.8–83.5). Treatment was well-tolerated,
with no new safety signals.
These results suggest that MSI status may have signif-
icant implication in therapeutic options. Immune check-
point blockade inhibition is less toxic than chemothera-
peutic regimens and can provide significant benefits to the
advanced cancer patients whose conditions are usually
weak. If microsatellite stability is validated as a biomarker
of immune checkpoint inhibitor efficacy, it will prove ex-
ceptionally useful in selecting patients most likely to ben-
efit from such therapies.
In theory, immune checkpoint inhibition may benefit pa-
tients with earlier-stage disease as well, and this is an impor-
tant research question to be addressed in the near future.
Positive results in these groups could potentially spare these
patients’ chemotherapy and expand the number of patients
who could benefit from less toxic immunotherapy.
Ere of Universal MSI Testing
Lynch syndrome is currently under-recognized, under-
diagnosed and under-managed. For example, an estimated
175,000 people have Lynch syndrome in the UK but a stag-
gering 95% of those do not know they have it. This is due to
lacking of efficient, systematic testing system [62]. It is vital
that people who have Lynch syndrome are identified, so they
can take steps to reduce their risk of recurrence or for family
members, of preventing cancer from developing.
MSI testing with either immunohistochemistry or PCR-
based method is found to be cost-effective, sensitive, specific
and is getting widely accepted. Therefore, several organiza-
tions including the US Multi-Society Task Force on
Colorectal Cancer [26], the US National Comprehensive
Cancer Network (NCCN) [63] and the UK National Institute
for Health and Care Excellence (NICE) [64] have recom-
mended testing all patients with colorectal cancer for Lynch
syndrome; the tumor should be tested for mismatch repair by
either DNA analysis or immunohistochemistry for MLH1,
MSH2, MSH6 and PMS2 proteins.
Expanding MSI testing to all people with colorectal cancer
will certainly increase the detection of Lynch syndrome. This
can lead to increased surveillance and improved patient out-
comes through earlier diagnosis and treatment. Meanwhile,
given the evolving role of MSI in prognostic estimation and
therapeutic efficiency prediction, the universal testing will
have important implications in colorectal cancer diagnosis
and personalized therapeutic approach.
Conclusion
Screening for MSI-H colorectal cancers is clinically sig-
nificant in detecting Lynch syndrome, predicting progno-
sis and determining the application of oncological treat-
ment for colorectal cancers. Recent studies on the poten-
tial role of MSI in targeted immunotherapy for metastatic
colorectal carcinomas have shown that testing MSI status
in these patients may be critical in precision medicine [11,
58–60]. There is a clear trend toward universal testing of
newly diagnosed colorectal cancers for evidence of micro-
satellite instability. Notably, some of extra-colonic can-
cers, such as endometrial carcinoma, gastric carcinoma
and ovarian carcinoma, also exhibit MSI-H profile, and
it is possible that MSI status may eventually become an
important prognostic and predictive marker in tumors be-
yond the colon [65–67]. At the present moment, multiple
clinical trials are ongoing, and in the near future, our
knowledge about MSI in targeted immunotherapy will
increase as a consequence of the completion of these on-
going studies.
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